Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab (INNOVATIONS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00536640
Recruitment Status : Completed
First Posted : September 28, 2007
Last Update Posted : June 12, 2013
Roche Pharma AG
Information provided by (Responsible Party):
Aktion Bronchialkarzinom e.V.